141 related articles for article (PubMed ID: 34979067)
41. Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: a pilot safety study.
Blanquer M; Moraleda JM; Iniesta F; Gómez-Espuch J; Meca-Lallana J; Villaverde R; Pérez-Espejo MÁ; Ruíz-López FJ; García Santos JM; Bleda P; Izura V; Sáez M; De Mingo P; Vivancos L; Carles R; Jiménez J; Hernández J; Guardiola J; Del Rio ST; Antúnez C; De la Rosa P; Majado MJ; Sánchez-Salinas A; López J; Martínez-Lage JF; Martínez S
Stem Cells; 2012 Jun; 30(6):1277-85. PubMed ID: 22415951
[TBL] [Abstract][Full Text] [Related]
42. Diaphragmatic CMAP amplitude from phrenic nerve stimulation predicts functional decline in ALS.
Miranda B; Gromicho M; Pereira M; Pinto S; Swash M; de Carvalho M
J Neurol; 2020 Jul; 267(7):2123-2129. PubMed ID: 32253508
[TBL] [Abstract][Full Text] [Related]
43. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis.
Fournier CN; Schoenfeld D; Berry JD; Cudkowicz ME; Chan J; Quinn C; Brown RH; Salameh JS; Tansey MG; Beers DR; Appel SH; Glass JD
Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):242-249. PubMed ID: 29308669
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.
Gordon PH; Moore DH; Miller RG; Florence JM; Verheijde JL; Doorish C; Hilton JF; Spitalny GM; MacArthur RB; Mitsumoto H; Neville HE; Boylan K; Mozaffar T; Belsh JM; Ravits J; Bedlack RS; Graves MC; McCluskey LF; Barohn RJ; Tandan R;
Lancet Neurol; 2007 Dec; 6(12):1045-53. PubMed ID: 17980667
[TBL] [Abstract][Full Text] [Related]
45. Long-term survival of a patient with amyotrophic lateral sclerosis (ALS) who received autologous adipose-derived mesenchymal stem cells.
Shigematsu K; Takeda T; Komori N; Urushihata N; Oki K; Tahara K; Yamagishi H
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4086-4090. PubMed ID: 34156687
[TBL] [Abstract][Full Text] [Related]
46. Effects of early introduction of non-invasive positive pressure ventilation based on forced vital capacity rate of change: Variation across amyotrophic lateral sclerosis clinical phenotypes.
Elamin EM; Wilson CS; Sriaroon C; Crudup B; Pothen S; Kang YC; White KT; Anderson WM
Int J Clin Pract; 2019 Jan; 73(1):e13257. PubMed ID: 30230161
[TBL] [Abstract][Full Text] [Related]
47. Rates of progression of weight and forced vital capacity as relevant measurement to adapt amyotrophic lateral sclerosis management for patient Result of a French multicentre cohort survey.
Clavelou P; Blanquet M; Peyrol F; Ouchchane L; Gerbaud L
J Neurol Sci; 2013 Aug; 331(1-2):126-31. PubMed ID: 23809193
[TBL] [Abstract][Full Text] [Related]
48. Treating amyotrophic lateral sclerosis with allogeneic Schwann cell-derived exosomal vesicles: a case report.
Goldschmidt-Clermont PJ; Khan A; Jimsheleishvili G; Graham P; Brooks A; Silvera R; Goldschmidt AJP; Pearse DD; Dietrich WD; Levi AD; Guest JD
Neural Regen Res; 2024 Apr; ():. PubMed ID: 38922880
[TBL] [Abstract][Full Text] [Related]
49. The amyotrophic lateral sclerosis functional rating scale predicts survival time in amyotrophic lateral sclerosis patients on invasive mechanical ventilation.
Lo Coco D; Marchese S; La Bella V; Piccoli T; Lo Coco A
Chest; 2007 Jul; 132(1):64-9. PubMed ID: 17475635
[TBL] [Abstract][Full Text] [Related]
50. Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis.
Sufit RL; Ajroud-Driss S; Casey P; Kessler JA
Amyotroph Lateral Scler Frontotemporal Degener; 2017 May; 18(3-4):269-278. PubMed ID: 28166654
[TBL] [Abstract][Full Text] [Related]
51. Association between nutritional status and disease severity using the amyotrophic lateral sclerosis (ALS) functional rating scale in ALS patients.
Park Y; Park J; Kim Y; Baek H; Kim SH
Nutrition; 2015; 31(11-12):1362-7. PubMed ID: 26429656
[TBL] [Abstract][Full Text] [Related]
52. Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
Glassberg MK; Minkiewicz J; Toonkel RL; Simonet ES; Rubio GA; DiFede D; Shafazand S; Khan A; Pujol MV; LaRussa VF; Lancaster LH; Rosen GD; Fishman J; Mageto YN; Mendizabal A; Hare JM
Chest; 2017 May; 151(5):971-981. PubMed ID: 27890713
[TBL] [Abstract][Full Text] [Related]
53. [Development of a telephone survey system for patients with amyotrophic lateral sclerosis using the ALSFRS-R (Japanese version) and application of this system in a longitudinal multicenter study].
Atsuta N; Watanabe H; Ito M; Nakamura R; Senda J; Kato S; Sobue G
Brain Nerve; 2011 May; 63(5):491-6. PubMed ID: 21515929
[TBL] [Abstract][Full Text] [Related]
54. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
[TBL] [Abstract][Full Text] [Related]
55. Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS.
Wills AM; Garry J; Hubbard J; Mezoian T; Breen CT; Ortiz-Miller C; Nalipinski P; Sullivan S; Berry JD; Cudkowicz M; Paganoni S; Chan J; Macklin EA
BMC Neurol; 2019 May; 19(1):104. PubMed ID: 31142272
[TBL] [Abstract][Full Text] [Related]
56. Elimination Rate of Serum Lactate is Correlated with Amyotrophic Lateral Sclerosis Progression.
Zhang YJ; Fan DS
Chin Med J (Engl); 2016 Jan; 129(1):28-32. PubMed ID: 26712429
[TBL] [Abstract][Full Text] [Related]
57. Is cell-based therapy more efficacious for people with amyotrophic lateral sclerosis/motor neuron disease than placebo or no treatment? - A Cochrane review summary with commentary.
Ceravolo MG
NeuroRehabilitation; 2020; 46(4):613-615. PubMed ID: 32538885
[TBL] [Abstract][Full Text] [Related]
58. Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial.
Min JH; Hong YH; Sung JJ; Kim SM; Lee JB; Lee KW
J Korean Med Sci; 2012 Feb; 27(2):200-6. PubMed ID: 22323869
[TBL] [Abstract][Full Text] [Related]
59. Adaptation to Turkish and Reliability Study of the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R).
Koç F; Balal M; Demir T; Alparslan ZN; Sarica Y
Noro Psikiyatr Ars; 2016 Sep; 53(3):229-233. PubMed ID: 28373799
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
de la Rubia JE; Drehmer E; Platero JL; Benlloch M; Caplliure-Llopis J; Villaron-Casales C; de Bernardo N; AlarcÓn J; Fuente C; Carrera S; Sancho D; GarcÍa-Pardo P; Pascual R; JuÁrez M; Cuerda-Ballester M; Forner A; Sancho-Castillo S; Barrios C; Obrador E; Marchio P; Salvador R; Holmes HE; Dellinger RW; Guarente L; Estrela JM
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Feb; 20(1-2):115-122. PubMed ID: 30668199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
